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Objective: Despite the well‐known negative impacts of cancer and anticancer therapies on
cognitive performance, little is known about the cognitive compensatory processes of older
patients with cancer. This study was designed to investigate the cognitive compensatory pro-
cesses of older, clinically fit patients with hematologic malignancies undergoing chemotherapy.
Methods: We assessed 89 consecutive patients (age ≥ 65 y) without severe cognitive impairment
and 89 age‐, sex‐, and education level‐matched healthy controls. Cognitive compensatory processes
were investigated by (1) comparing cognitive performance of patients and healthy controls in novel
(first exposure to cognitive tasks) and non‐novel (second exposure to the same cognitive tasks) con-
texts, and (2) assessing psychological factors that may facilitate or inhibit cognitive performance, such
asmotivation, psychological distress, and perceived cognitive performance.We assessed cognitive per-
formance with theTrail‐Making, Digit Span and FCSR‐IR tests, psychological distress with the Hospital
Anxiety andDepression Scale, and perceived cognitive performancewith the FACT‐Cogquestionnaire.
Results: In novel and non‐novel contexts, average cognitive performances of healthy controls
were higher than those of patients andwere associatedwithmotivation. Cognitive performance of
patients was not associated with investigated psychological factors in the novel context but was
associated with motivation and psychological distress in the non‐novel context.
Conclusions: Older, clinically fit patients with hematologic malignancies undergoing chemo-
therapy demonstrated lower cognitive compensatory processes compared to healthy controls.
Reducing distress and increasing motivation may improve cognitive compensatory processes of
patients in non‐novel contexts.
KEYWORDS
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Aging,1 cancer,2 and related treatments3 may have negative impacts on
cognitive performance through multiple processes, includinglly to this work and should be
td. wileyonlinelibinflammation, DNA damage, or telomere shortening.4,5 Studies exam-
ining cognitive impairment in older cancer patients found that the
major altered domains were processing speed,6-8 executive func-
tion,7,9,10 attention,9,11 and memory.7,9 Meanwhile, other studies
reported that some older cancer patients do not develop these impair-
ments.12-14 If these results may reflect a low sensitivity of cognitivePsycho‐Oncology. 2017;26:2086–2093.rary.com/journal/pon
LIBERT ET AL. 2087task used (Mini‐Mental State Examination (MMSE) or Telephone Inter-
view of Cognitive Status), this finding may also support the hypothesis
that some patients use cognitive compensatory processes, probably by
recruiting additional brain areas,15 to develop and use additional
resources and strategies to perform a task. Clinically, these processes
could be reflected, for example, in a feeling of not being able to func-
tion as before, a need to increase mental effort for a well‐known task,
and difficulties to benefit from previous experience.
Although currently impossible to study directly, cognitive compen-
satory processes can be assessed indirectly through neuroimaging or
longitudinal studies comparing cognitive performance of patients and
healthy controls. In longitudinal studies, these processes should be
studied by assessing the cognitive performance of older cancer
patients in novel and non‐novel contexts and by assessing psychologi-
cal factors that may facilitate or inhibit cognitive performance.
Cognitive performance in novel versus non‐novel contexts may require
different levels of compensatory processes. In a novel context, optimal
performance requires memory skills to memorize instructions, as well
as executive skills (eg, planning, inhibition, and elaboration strategies) to
achieve a goal and reduce interference caused by the novel context itself.
In a non‐novel context, optimal performance requires the ability to
remember and use previously acquired information through specific
strategies, such as category clustering formemory tasks,16 leading to faster
performance, in a less varied, easier manner.17 Moreover, certain psycho-
logical factors may facilitate or inhibit cognitive performance.18 This
modulation reflects the use or nonuse of resources and strategies, known
as cognitive compensatory processes, to optimize cognitive functioning.
There are several arguments for collecting novel and non‐novel
task performances to better understand cognitive compensatory pro-
cesses.19 It should be recalled that, compared to a non‐novel task, a
novel task requires more cognitive efforts. This is certainly the case
when a subject is exposed for the first time to a neuropsychological
task. When a subject is re‐exposed to this task, he may benefit from
his previous experience. This benefit is called a “test‐retest” effect.
Assessing to what extent a person may benefit of such effect may
inform about cognitive compensatory processes.
The aim of this study was to investigate the existence of altered
cognitive compensatory processes among older, clinically fit patients
with hematologic malignancies undergoing chemotherapy through a
longitudinal cohort design. Patients and healthy controls, matched for
age, sex, and educational level, had their cognitive performance tested
twice, in novel and non‐novel contexts. The first exposure of a subject
to a cognitive task is considered a good proxy for exposure to a novel
context. A second exposure, 1 month later, of the same subject to the
same cognitive task is considered a good proxy for exposure to a non‐
novel context. Influences of psychological factors, including motivation,
psychological distress, and perceived cognitive performance, as poten-
tial inhibitors or facilitators of cognitive performance were assessed for
both contexts. In this way, cognitive performance and its association
with the chosen psychological factors were assessed longitudinally.
Beside the a priori assumption that cancer and related treatments
may impair the cognitive performance of older patients, 2 hypotheses
regarding the cognitive functioning of older, clinically fit patients were
made to investigate cognitive compensatory processes. First, we
hypothesized that, contrary to healthy controls, patients would notdemonstrate improvement in cognitive performance over time (a prac-
tice effect), due to their reduced ability to use cognitive compensatory
processes. Second, considering a potential floor effect related to age,
cancer, and related treatments, we hypothesized that no association
between patients' cognitive performance, motivation to undertake a
cognitive task, psychological distress, and perceived cognitive perfor-
mance would be found in a novel context, reflecting the important cog-
nitive load required to perform a novel task and related difficulties to
benefit from psychological facilitator factors. We hypothesized that, in
a non‐novel context, an association would be found between patients'
cognitive performance and these psychological factors, reflecting the
reduced cognitive load required to perform a non‐novel task.2 | METHODS
2.1 | Patients and setting
This study was conducted in 6 Belgian hospitals and was approved by
the local ethics committees. All consecutive patient volunteers fulfilling
the inclusion criteria were invited to participate and provided written
informed consent. Recruited patients were at least 65 years old, had
hematologic malignancies, had been admitted to begin chemotherapy,
were able to speak French, and were assessed as clinically fit by their
physician before treatment. The term “clinically fit” refers to the fact
that the patient has no geriatric syndrome and/or irreversible comor-
bidity impairing daily functioning. Patients hospitalized for palliative
care, those with severe cognitive impairments (as assessed by their
physicians), and those who could not complete scheduled assessments
for physical or psychological reasons were excluded.
Healthy controls, matched for age (±5 y), sex, and education level,
were also recruited. To ensure that these individuals were representa-
tive of the global population of this age group, healthy controls with
previous medical or surgical history (including cancer) or psychiatric
disorders were not excluded. However, healthy controls with current
acute medical, neurological, or psychiatric conditions were excluded.
Finally, healthy controls who had previously benefitted from chemo-
therapy were excluded, to allow comparison between the included
groups on the studied variables.
The first assessment (novel context) was conducted from the first
48 hours before the start of chemotherapy to the 48 hours after the start
of chemotherapy (baseline for healthy controls). The second assessment
(non‐novel context) was conducted 1 month later (±15 days). Each
assessment lasted approximately 1 to 1.5 hours. Except sociodemographic
data, all assessment tools were given at the 2 time points.2.2 | Assessment tools
2.2.1 | Sociodemographic and medical characteristics
Patients and healthy controls provided demographic information,
including age, sex, and educational level. Physicians provided patients'
medical characteristics, including diagnosis, time since diagnosis, dis-
ease status, prognosis, number of comorbidities, and hematological
treatment characteristics.
2088 LIBERT ET AL.2.2.2 | Physical functioning status
Physical functioning status was assessed by using the following vali-
dated tools: the Karnofsky Performance Score (total score ranged from
0 to 100) and the Katz ADL20 (Activities of Daily Living; total score
ranged from 6 to 24) and Lawton IADL21 (Instrumental Activities of
Daily Living; total score ranged from 8 to 32); measures of activities
of daily living (higher score indicated better physical functioning
status).2.2.3 | Cognitive performance
Cognitive performance was assessed through an objective assessment
consisting of 3 tools that included domains likely affected by cancer
and anticancer therapy. These tools were the Wechsler Digit Span
Test, the Free and Cued Selective Reminding Test with Immediate
Recall (FCSR‐IR), and Trail‐Making Test parts A and B (TMT A and B).
The Wechsler Digit Span Test (WAIS‐IV)22 and a shortened ver-
sion of the FCSR‐IR were used to assess working and short‐term mem-
ory. During the first test, digits were verbally presented to participants
at a rate of 1 per second. Participants were asked to repeat digits in the
same order for the forward digit span or reverse order for the back-
ward digit span. In the current study, the number of correct trials
was used. During the second test consisting of a controlled learning
procedure developed by Grober and Buschke,23 participants were pre-
sented with a list of 16 written words. They were asked to associate
each word with a given category cue to memorize these words (imme-
diate recall). Thereafter, participants were invited to observe a 20‐sec-
ond distractor period (count back) to prevent rehearsal. Subsequently,
free recall and cued recall were assessed. This procedure was repeated
after a 20‐second distractor period. An alternate form was used at the
second assessment. Because first and second free recalls were highly
correlated, only the immediate and the second free recalls were used
in this study.
The TMT A and B24 were used to assess processing speed and
executive function. TMT A requires to connect 25 encircled numbers
as quickly as possible. TMT B requires to alternate consecutive
sequences of numbered and lettered circles. Shorter times to comple-
tion (in seconds) indicated better performance. The number of errors
was also recorded. Regarding part B, as we decided to consider globally
cognitive performance, it was decided to take into account both per-
severative and normal errors. BecauseTMT A and B were highly corre-
lated, only results of TMT B were used in this study. On the basis of
these 3 tools, we calculated a global cognitive composite z‐score










i;j þ zTMTB Error sð Þi;j
6
:
CPSi,j is the cognitive performance score for patient i in context j;
and zx i,j is the z‐score for variable x and patient i in context j. As
higher zTMTB Timei;j and z
TMTB Error sð Þ
i;j indicate worse performance, these z‐
scores were reversed to calculate the global composite cognitive score.2.2.4 | Psychological characteristics
Motivation
After completing perceived cognitive performance and before complet-
ing objective neuropsychological tasks, patients and healthy controls
were asked to report their level of motivation to undertake these tasks
on a 100‐mm visual analogue scale, ranging from “not at all” to “a lot.”
This sequence has been chosen to fit with the objectives of this study.
Perceived cognitive performance
The FACT‐Cog (Functional Assessment of Cancer Therapy‐Cognitive
Function) Scale is a self‐reported measure of cognitive impairment
and its impact on the quality of life (QOL) of patients. This 37‐item
translated and validated with French speaking patients with cancer25
consists of 4 subscales: perceived cognitive impairment, comments
from others, perceived cognitive ability, and impact on QOL.26 Only 2
subscales, Perceived Cognitive Impairment (PCI; 18 items; score range:
0‐72) and Perceived Cognitive Ability (PCA; 7 items; score range 0–28),
were used in this study to calculate a global composite perceived cog-
nitive performance z‐score (PCPS), which consists of a mean of these






TheHospital Anxiety andDepression Scale27was used to assess the psy-
chological distress of patients and healthy controls (total score ranged
from 0 to 42, higher score indicated higher psychological distress).
2.3 | Statistical analysis
Initially, a descriptive analysis of the 2 groups was prepared. Intergroup
and intragroup comparisons of cognitive performance and psychologi-
cal characteristics were computed by using nonparametric tests, as
appropriate (Mann–Whitney or Wilcoxon tests). Univariate relation-
ships between groups' cognitive performance and psychological factors
were evaluated by using nonparametric tests (Spearman correlations).
Group‐by‐time effects were analyzed by using a two‐way repeated
measures multivariate analysis of variance. Finally, backward stepwise
linear regressionmodels were computed to assess relationships between
psychological factors and cognitive performance for each group in novel
and non‐novel contexts. All psychological variables with univariate P
values ≤0.05 were entered into the model. All tests were two‐tailed,
and alpha was set at 0.05. Analyses were performed with SPSS software
(version 23.0 for Windows; SPSS, Chicago, Illinois).3 | RESULTS
3.1 | Subjects
Among 293 eligible inpatients, 98 refused to participate in the study.
Twenty patients withdrew during the first assessment. In addition, 51
patients did not complete the neuropsychological assessment in the
novel context and were excluded from the study. Three patients died
TABLE 1 Participants' sociodemographic and medical characteristics
Patients (n = 89) Healthy Controls (n = 89)
n % Mean Std n % Mean Std
Sociodemographic characteristics
Age 72 5 72 6
Gender
Male 58 65 58 65
Female 31 35 31 35
Education
Less than junior high school 26 29 26 29
Junior high school 22 25 22 25
High school graduation or more 41 46 41 46
Medical characteristics at the time of chemotherapy initiation
Diagnosis
Lymphoma, multiple myeloma, chronic lymphocytic leukemia 70 79 NA NA
Acute myelogenous leukemia, chronic myelomonocytic leukemia, myelodysplasia 18 20 NA NA
Acute lymphocytic leukemia 1 1 NA NA
Time since diagnosis (months) 22 41 NA NA
First diagnosis
Yes 62 70 NA NA
No 27 30 NA NA
Disease status
Complete remission, partial remission, minor remission or no change 13 15 NA NA
In progression 11 12 NA NA
Too early to evaluate 65 73 NA NA
Prognosis
< 1 y 3 4 NA NA
≥ 1 y 27 30 NA NA
Too early to evaluate 59 66 NA NA
Previous other cancer diagnosis
Yes 24 27 NA NA
No 65 73 NA NA
Number of commorbidities 3 2 NA NA
Physical functioning status
Karnofsky performance score 83 13 NA NA
Activities of daily living 24 1 NA NA
Instrumental activities of daily living 32 2 NA NA
30 ± 15 days after the time of chemotherapy initiation
Medical characteristics
Number of commorbidities 3 2 NA NA
Physical functioning status
Karnofsky performance score 78 16 NA NA
Activities of daily living 24 1 NA NA
Instrumental activities of daily living 30 3 NA NA
Treatment characteristics
Hematological treatment
Chemotherapy 82 92 NA NA
Autologous bone marrow transplant (with induction chemotherapy) 4 5 NA NA
Allogeneic bone marrow transplant (with induction chemotherapy) 3 3 NA NA
Chemotherapy courses number
1 55 62 NA NA
2 32 36 NA NA
3 2 2 NA NA
(Continues)
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TABLE 1 (Continued)
Patients (n = 89) Healthy Controls (n = 89)
n % Mean Std n % Mean Std
Hospitalization needed for chemotherapy
No 43 48 NA NA
Yes 46 52 NA NA
Abbreviation: Std, standard deviation; NA, not applicable. No significant difference was found between patients and healthy controls regarding age
(P = 0.842), gender (Chi‐squared(1) = 0; P = 1.000), and education (Chi‐squared(2) = 0; P = 1.000).
2090 LIBERT ET AL.before the second evaluation. During the second assessment, 26
patients withdrew and 5 did not finish the complete neuropsychologi-
cal assessment. One patient was excluded from statistical analysis
because the interval between the 2 assessments was too long
(63 days). Thus, analyses included 89 patients who were being treated
in outpatient or inpatient settings, according to their diagnoses and
treatments. It should be noted that patients who dropped out after
the completion of the first assessment were not significantly different
from included patients considering neuropsychological tasks.
Table 1 lists the sociodemographic and medical characteristics of
patients. Age, sex, and educational level distributions of matched
healthy controls were the same as those of patients. Table 2 displays
the cognitive and psychological characteristics of participants in novel
and non‐novel contexts. For cognitive performance, a group effect
was found, but no time or group‐by‐time effect was found. Group
effects were found regarding psychological characteristics (perceived
cognitive performance, motivation, and psychological distress). A time
effect was found for perceived cognitive performance. Finally, a
group‐by‐time effect was found for perceived cognitive performance.
Table 3 lists the psychological characteristics associated with the cogni-
tive performance of patients and healthy controls. Cognitive perfor-
mance of healthy controls was associated with motivation in novel
and non‐novel contexts. Cognitive performance of patients was not sig-
nificantly associated with investigated psychological characteristics in
the novel context but was associated with perceived cognitive perfor-
mance, motivation, and psychological distress in the non‐novel context.
Three backward, stepwise, linear regression analyses were con-
ducted (Table 4). For analyses of the cognitive performance of healthy
controls in the novel and non‐novel contexts, only motivation was
entered into the models. Motivation predicted the cognitive perfor-
mance of healthy controls in the novel context and non‐novel context,
with proportions of explained variance of 18%. For analysis of the cog-
nitive performance of patients in the non‐novel context, 3 variables
were entered into the model: perceived cognitive performance, moti-
vation, and psychological distress. Performance of patients in the
non‐novel context was predicted by motivation and psychological dis-
tress, with a proportion of explained variance of 19%.4 | DISCUSSION
To our knowledge, this longitudinal cohort study is the first designed
to investigate cognitive compensatory processes of older, clinically fit
patients with hematologic malignancies undergoing chemotherapy,through the cognitive performance and associated psychological fac-
tors in novel and non‐novel contexts. As expected in our hypothesis
in the light of available studies about hematologic malignancies,28
healthy controls performed more optimally than patients in both con-
texts. The findings did not confirm our first hypothesis that patients
would not improve their cognitive performance over time compared
to healthy controls. Indeed, no practice effect was found for healthy
controls or for patients. Our findings did confirm our second hypothe-
sis that there would be an association between patients' cognitive per-
formance and psychological factors in the non‐novel context. A
significant positive association was found between the cognitive per-
formance of healthy controls and motivation in both contexts, whereas
no significant association was found for patients in the novel context.
In the non‐novel context, however, a significant positive association
between cognitive performance and motivation and a significant neg-
ative association between cognitive performance and psychological
distress were found.
Why the results found in patients are not similar to those found in
healthy controls? At a cognitive level, our results reinforce the idea
that older, clinically fit patients with hematologic malignancies under-
going chemotherapy not only perform less optimally in both novel
and non‐novel contexts but also (1) do not improve in performance
over time (healthy controls did not improve, either) and (2) do not ben-
efit from motivation in a novel context, although low motivation and
high psychological distress may decrease performance in a non‐novel
context. Taken together, these findings suggest that such patients
have difficulty in using and/or developing additional resources to com-
pensate for potentially altered cognitive performance due to cancer,
anticancer therapy, and their psychological consequences. In other
words, for these patients, it is easier to compensate for altered cogni-
tive performance in a non‐novel context, in the presence of a high
motivation and a low psychological distress level, to complete cogni-
tive tasks. It should be underlined at this level that patients have a sig-
nificant higher level of psychological distress compared to healthy
controls at the 2 assessment points although there is no difference in
the evolution over time of psychological distress between the 2
assessments both for patients and for healthy controls.
Previous studies have emphasized cognitive changes related to
cancer and chemotherapy among older patients with cancer. To our
knowledge, however, this is the first study showing differences
between older, clinically fit patients with hematologic malignancies
undergoing chemotherapy and matched healthy controls in terms of




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2092 LIBERT ET AL.4.1 | Clinical implications
Our results may have an important clinical implication: Healthcare pro-
fessionals should be aware that clinically fit, older patients with hema-
tologic malignancies undergoing chemotherapy already experience
altered cognitive compensatory processes. To date, no recommenda-
tion has been made to support the cognitive compensatory processes
of such patients. Based on the results of the current study, 2 recom-
mendations could be made to optimize support. First, healthcare pro-
fessionals should inform patients that, during treatment, their
cognitive compensatory processes may be less effective, in order to
normalize their subjective feelings. Second, patients should be informed
that, although in a novel context it may be difficult for them to compen-
sate for their altered cognitive functioning, increasing their motivation
and regulating their psychological distress may improve their cognitive
compensatory processes in a non‐novel context. It should be recalled
at this level the negative impact of distress on cognitive performance.294.2 | Study limitations
Some limitations of the study should be mentioned. First, as our study
included only clinically fit patients with hematologic malignancies, our
results may not be generalizable to more vulnerable populations or to
patients with solid tumors. Second, patients were assessed only during
the first month of chemotherapy treatment. Thus, our results do not
reflect patients' later cognitive functioning. Third, by focusing on psy-
chological factors, analyses performed did not control for other poten-
tial confounding factors, such as fatigue and pain.5 | CONCLUSION
In conclusion, the results of this study indicate that older, clinically fit
patients with hematological malignancies undergoing chemotherapy
are at risk for altered cognitive compensatory processes in novel and
non‐novel contexts, suggesting that these processes should be
addressed in cancer care. Although these results improve understand-
ing of patients' cognitive compensatory processes, future studies
should identify underlying mechanisms of such processes, to optimize
potential revalidation interventions. Future studies should investigate
the capacity of other physical, psychological, and social factors, such
as physical exercise, perceived cognitive performance, and social sup-
port, to influence cognitive compensatory processes. Studies should
also investigate the effects of altered cognitive compensatory pro-
cesses on medical decision making, treatment compliance, daily func-
tioning, and general QOL of patients. As to our knowledge, there are
no other studies assessing cognitive compensatory processes in an
older cancer patient population; the results of this study should of
course be further studied. Finally, revalidation interventions that
account for psychological factors, such as motivation and perceived
cognitive performance, should be developed and tested to support
the cognitive compensatory mechanisms of older patients with cancer.
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